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Abstract
Recently developed vaccines provide a new way of controlling rotavirus in sub-Saharan Africa.
Models for the transmission dynamics of rotavirus are critical both for estimating current burden
from imperfect surveillance and for assessing potential effects of vaccine intervention strategies.
We examine rotavirus infection in the Maradi area in southern Niger using hospital surveillance
data provided by Epicentre collected over two years. Additionally, a cluster survey of house-
holds in the region allows us to estimate the proportion of children with diarrhea who consulted
at a health structure. Model fit and future projections are necessarily particular to a given
model; thus, where there are competing models for the underlying epidemiology an ensemble
approach can account for that uncertainty. We compare our results across several variants of
Susceptible-Infectious-Recovered (SIR) compartmental models to quantify the impact of model-
ing assumptions on our estimates. Model-specific parameters are estimated by Bayesian inference
using Markov chain Monte Carlo. We then use Bayesian model averaging to generate ensemble
estimates of the current dynamics, including estimates of R0, the burden of infection in the region,
as well as the impact of vaccination on both the short-term dynamics and the long-term reduction
of rotavirus incidence under varying levels of coverage. The ensemble of models predicts that the
current burden of severe rotavirus disease is 2.9 to 4.1% of the population each year and that a
2-dose vaccine schedule achieving 70% coverage could reduce burden by 37-43%.
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1 Introduction
Diarrheal disease is the second leading cause of death around the world for children under 5
years of age [6]. Though there are many infectious causes of diarrheal disease in children, rotavirus
is the leading cause of gastroenteritis [8, 43, 41]. In many countries, better sanitation, hygiene and
access to care have reduced the burden of diarrhea [11, 22]. Despite this trend, the proportion of
diarrheal hospitalizations attributable to rotavirus increased between 2000 and 2004 [30]. The recent
development of new prophylactic vaccines for rotavirus is a promising advance in the prevention of
diarrheal disease and the reduction of overall childhood mortality [31, 25].
Observation of rotavirus dynamics and estimation of the burden of rotavirus disease is limited
both by non-specific surveillance and under-reporting. The dynamics of rotavirus transmission must
often be inferred from non-specific temporal surveillance of diarrheal disease that includes multiple
causes. This is analogous to the dynamics of specific influenza strains, which are commonly inferred
from non-specific time series surveillance of influenza-like illness (ILI) that includes infection by
multiple influenza strains (influenza A and B), as well as additional viral infections, for example
parainfluenza, coronavirus, rhinovirus [35, 10]. In sub-Saharan Africa, the cause of diarrheal disease
is often unknown due to a lack of diagnostic capacity [28]. Even when the cause of disease is known,
an unknown fraction of cases will occur in the community and never be recorded by the health system,
leading to a potentially significant level of under-reporting. Dynamic models in general, and so-called
state-space models in particular, have been an important tool in the assessment of disease burden from
non-specific or imperfect surveillance [19, 16, 7]. We estimate the burden of rotavirus in the Maradi
region of Niger by synthesizing two sources of data. We use hospital surveillance data collected by
Epicentre for the incident cases over time, including lab-confirmation to assess the likelilhood that
a case of severe diarrhea is caused by rotavirus. In addition, we use a cluster survey of households
conducted to estimate the proportion of diarrheal disease cases in the region seeking care. The latter
is used to help estimate the reporting rate.
State-space models rely on the temporal correlation in a dynamic model to make the unobservable
true state of the system, that is, the incidence of the pathogen of interest, estimable from noisy
or imperfectly sampled data [21]. Thus, the inference about disease burden is conditional on the
structure of the underlying dynamic model. For pathogens with well characterized epidemiology,
such as measles and influenza, the application of state-space models to infer disease burden and
transmission dynamics has become common [19, 9, 7, 38]. The dynamics of rotavirus, which itself
comprises multiple strains that result in varying levels of cross-protective immunity to other strains,
has been variously described by a suite of different models [32]. Therefore, inference about rotavirus
burden is limited both by imperfect surveillance of rotavirus infection and uncertainty about the
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underlying transmission dynamics. Rather than condition our analysis on any one model, we fit
the observed time series to a suite of 5 different model structures and assumptions to account for
uncertainty in model parameters as well as the dynamics represented in the models themselves.
While the development of several novel rotavirus vaccines is a promising advance for the control
of diarrheal disease in children, the potential impact of the introduction of these vaccines at the
population-scale is uncertain. The predicted impact of vaccine introduction may depend both on the
efficacy of the vaccine and model structure; for example [32] proposed alternative models for boosting
of immunity following sequential exposure to rotavirus. Bayesian model averaging (BMA) [4, 18]
allows for the integration of predictions of multiple models, weighted by their posterior support, to
generate a single ensemble estimate that accounts for uncertainty in model selection. Here, via BMA,
we use the ensemble of fitted models to predict the short-term and long-term impact of vaccination
on rotavirus incidence. We then estimate the predicted impact using the vaccine efficacy from two
different studies. Our ensemble approach predicts that the current burden of severe rotavirus disease
is 2.9 to 4.1% of the population each year and that a 2-dose vaccine schedule achieving 70% coverage
could reduce burden by 37-43%.
2 Material and Methods
We use data from two sources: a time series of clinic admissions for diarrheal disease and a
community based survey of health-seeking behavior. Clinic surveillance covers a collection of health
centers and district hospitals from four districts in the Maradi region of Niger including Aguie, Guidan
Roumdji, Madarounfa, and the city of Maradi. A total of 9,590 cases of diarrhea in children under 5
were recorded from December 23, 2009 to March 31, 2012 (118 weeks). For each patient age in months,
village of origin, date of consultation were recorded. Also noted were potential symptoms including
temperature, duration of diarrhea before consultation, presence of blood in the stool, presence and
duration of vomiting, and level of dehydration. In each case a rapid test was administered for detecting
rotavirus. 2,921 cases tested positive for rotavirus via the rapid test. A subset of 378 cases testing
positive for rotavirus were also genotyped. While 32 separate strains were identified, more than two
thirds of positive cases were of strains G12P[8] or G2P[4].
The distributed nature of Niger’s healthcare system is a challenge for surveillance. Roughly a
third of all health centers in these districts were included. Notably absent were the many local health
posts staffed by community health workers. To estimate both the fraction of cases seeking care at a
health center, and the fraction seeking any level of care, a second source of data is needed. We use a
community survey [29] in the region of children under 5 to get estimates of these reporting rates.
A total of 2940 children under 5 were selected for inclusion in the cluster survey from households
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across the four districts. Clusters were allotted according to the population of each village from
census data. Sampling weights accounted for household composition and the relative populations of
the districts. Among those surveyed, 1099 caregivers reported at least one episode of diarrhea during
the recall period of 27 days. Respondents reported whether they sought care at a health structure.
We use the reporting rate of severe diarrhea, which is defined as the presence of acute watery diarrhea
and the presence of two or more of the signs of loss of consciousness, sunken eyes, and an incapacity
to drink or drinking very little.
From the cluster survey we determine that an estimated total of 42.9% of caregivers who reported
severe diarrhea consulted at a health center (95%CI : (33.1%, 52.7%)). The rest either sought care
at a district hospital, local health post or did not seek care at a formal health structure. This
estimate is used as a proxy for the reporting rate of rotavirus. More specifically, this information is
used to construct an informative prior for our Bayesian approach (as described in the supplementary
material).
2.1 Model Overview
We consider a range of dynamic models for rotavirus transmission. Information linking individual-
level data on the course of infection to the between-person transmission of rotavirus is lacking, leading
to variation in the structure of mathematical models for rotavirus [32]. Using a range of different
models allows us to account for the uncertainty in estimation due to model choice. The five models
we consider are SIR-like compartmental models of transmission, building upon the models in [32].
We incorporate age into the model with separate compartments for ages from 0-1 month, 2-3 months,
4-5 months, 6-11 months, 12-23 months, and 24-59 months. Fixed parameters are estimated from
England and Wales data as described in [32].
Here we very briefly outline the main features of five models, Models A through E, based on the
SIR framework. Details of the model and inferential procedure are described in the supplementary
material. Model A tracks severe and mild rotavirus separately. Severe infections have larger force of
infections than mild infections. Unlike Model A, Models B-E assume successive infections and immu-
nity are obtained through repeated infections. Subsequent infections will have a reduced susceptibility
to infection and level of infectiousness. Model C allows for an incubation period of infections as well.
In Model D there is no temporary immunity during successive infections and immunity is granted
after all repeated infections. Model E assumes that full immunity can be obtained during succes-
sive infections. All model parameters are estimated via Markov chain Monte Carlo (MCMC) and
estimated burden over time were obtained from each model.
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2.2 Vaccination
We assume vaccination imparts immunity comparable to a natural infection, and consider a
strategy wherein a first dose is administered at 2 months of age and a second dose is administered
at 4 months. The vaccine was assumed to confer protection comparable to protection conferred by
primary infection following the first dose. The second dose confers additional protection comparable
to that conferred by secondary infection. For Model A, where the risk of infection does not decrease
based previous number of infections, a separate input parameter is used for the vaccine efficacy. The
vaccine efficacy is set to be equal to the predicted efficacy for Models B-E (see supplementary material
for details). We study the effect of the vaccine under varying levels of coverage. The short-term effect
of vaccination is assessed by looking at incidence over a five year period following introduction of
the vaccine. The long-term effect is measured by the yearly reduction in incident cases of Rotavirus
gastroenteritis (RVGE) measured 20 years after introduction of the vaccine. Field efficacy of a multi-
dose rotavirus vaccination strategy is uncertain. To reflect this uncertainty, we investigate the impact
of vaccination using the value of efficacy from two different studies. First based on the results of
[24], for low income countries, we assume a seroconversion rate of 63%. Second, a recent study of a
3-dose vaccination strategy in Niger [20] estimated efficacy of 66.7% with all doses. The details of
representing these two estimates of efficacy in the 5 models are presented in the supplement.
3 Results
We fit each model independently and estimate parameters. Then we calculate ensemble esti-
mates using Bayesian model averaging (BMA) [4, 18] to formalize uncertainty in model selection
(see supplementary material for details). Posterior model probabilities (PMP) measures how much
each model is supported by the data. Following the BMA approach, based on these probabilities, we
provide a weighted average of estimates from five different models. There is significant discordance
across models in the measures of model fit (Table 1). Model C, the model with incubation periods
performs the best. Notably, Model A, the only model that does not allow for successive infections
with decreased levels of infectiousness, performs significantly worse as measured by posterior model
probability.
3.1 Pre-vaccination
Our fitted models allow us to construct estimates of the burden in these four districts (Table
1). Of children under five, an approximate 3.5% per year develop severe RVGE as estimated by
Models B-D, though this estimate is lower for Model E and significantly larger for Model A. The
5
Model Probability R0 Burden
A 0 30.7 (25.8,34.3) 9.2 (8.1,10.1)
B 0.01 13.9 (12.7,15.4) 3.5 (3.1,3.8)
C 0.92 13.4 (11.7,15.3) 3.5 (3.1,3.9)
D 0.03 11.2 (9.4,12.7) 3.6 (3.2,4.1)
E 0.04 10.3 (9.5,12.6) 3.2 (2.9,3.5)
BMA 13.4 (10.3,15.4) 3.5 (2.9,4.2)
Table 1: For each model we provide posterior model probability (PMP), the basic reproductive number
R0, and estimated burden. Burden corresponds to yearly cases with severe RVGE (% of population).
The last row corresponds to the model-averaged (via Bayesian model averaging) versions of these
estimates.
basic reproductive number R0 is found as the largest eigenvalue of the next-generation matrix [14]
and significantly larger for Model A. BMA for burden and R0 are close to those of Model C, which
has the highest weight. In Figure 1, we plot our model projections with uncertainty for reported cases
of rotavirus as well as for all cases of severe RVGE. We also note that Models B-E predict a steep
decline in cases in children over 1y of age following the epidemic peak; cases in infants under 1y, by
contrast, are predicted to decline more slowly.
Figure 2 shows the BMA-based model projections which are close to those of Model C. However
we note that BMA-based projections have wider confidence intervals because averaged projections
incorporate model uncertainty.
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Figure 1: Burden estimates under the five fitted models. Dashed lines denote 95% confidence interval.
Top: weekly reported cases of RVGE and model projections. Middle: model projections of all severe
RVGE cases. Bottom: model projections of RVGE incidence by age. Lines are model projections
while points represent observed cases.
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Figure 2: Model-averaged (BMA) burden estimates from the five fitted models. Dashed lines denote
95% confidence interval. Left: weekly reported cases of RVGE and model projections. Middle: model
projections of all severe RVGE cases. Right: model projections of RVGE incidence by age. Lines are
model projections while points represent observed cases.
All of the fitted models are able to successfully capture the observed age distribution of cases
(Figure 3), though Models C and E predict noticeably more cases than observed for older children
(2-5 years). The models vary in their ability to capture the temporal dynamics. During the second
year of hospital surveillance we can see a secondary peak in the number of cases that is not captured
by our fitted model, although we did find that the model dynamics can produce this double peak
through an interaction of a high birth rate and seasonal variation when the seasonal forcing is stronger
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than that estimated here. BMA shows a similar trend as the Model C, which has the highest weight.
3.2 Projected Impact of Vaccination
Here we investigate the impact of vaccination based on the seroconversion rate for low socio-
economic settings [24]. In the supplementary material we provide the impact of vaccination using a
different value of efficacy which is measured based on a 3-dose strategy [20]. This was qualitatively
similar, but quantitatively small compared to the results in the main paper. Vaccination causes
a noticeable shift in the age distribution across Models B-E (Figure 3), with a higher proportion of
RVGE cases occurring in older children. This has significant benefits when considering the age-specific
mortality of rotavirus is higher for children under 2 years of age [27]. The BMA-based burden shows
a similar trend.
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Figure 3: Distribution of cases across age groups observed in the data (black dots), predicted by the
models (red lines), and predicted after vaccination has been introduced at 70% coverage (blue lines).
Over the short term, Models A-E predict an overall decline in total burden, but an increase in the
magnitude of peak incidence (Figure 4).
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Figure 4: Relative incidence of severe RVGE after vaccination has been introduced into the models
assuming 70% coverge, out to five years after vaccination has been introduced. The vaccination has
been introduced at 0 year.
Figure 5 provides short term and long term impact of vaccination which are model-averaged values
from five different models. The short term trend of vaccination impacts based on BMA is similar to
that of Model C. At equilibrium (long term), we can observe the reduction in severe rotavirus cases
with higher levels of coverage. For a fixed (70%) level of coverage, we predict 38.9% reduction of
severe RVGE (99%CI : (37.1%, 42.6%)) over the long-term. Based on the recent vaccine efficacy study
in [20], we predict 29.6% reduction (99%CI : (28.0%, 32.7%)) in RVGE over the long-term. Details
are provided in the supplementary material.
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Figure 5: Relative incidence of severe RVGE (Left), percent (Middle) and absolute (Right) long term
reduction in cases by coverage for Bayesian model averaging from the five fitted models. Dashed
lines denote 99% confidence interval. The vaccination has been introduced at 0 year. Variation in
reduction for a fixed (70%) level of coverage is demonstrated.
4 Discussion
Diarrheal disease is a major source of childhood morbidity and mortality. However, the multi-
etiology nature of diarrheal disease means that it is difficult, in the absence of lab confirmation, to
infer total burden or project the consequences of novel interventions. We have rich but short-term
9
data with which to understand the dynamic process; in combination with survey data on health-
seeking behavior; however, we can bring additional information to bear on the observation rate to
interpret the patterns from the non-specific clinic surveillance.
For rotavirus, the uncertainty inherent in imperfectly observed incidence is compounded by the
lack of a generally accepted model and debate about the underlying mechanisms that drive the
epidemiological response [32]. This motivates an ensemble approach, using a combination of different
models along with quantitative surveillance to get practical measures of burden and projections about
the operational impact of controls. This multi-model ensemble approach is common in geosciences
[26, 40, 42], where different assumptions on complex underlying processes can produce different climate
projections, which motivates a probabilistic forecast from a variety of models. A competing models
approach has been adapted to epidemiological problems as well, such as choosing an optimal strategy
for measles vaccination [36] and assessing the impact of control actions for foot and mouth disease
outbreaks [23].
Here we formally address these two sources of uncertainty, using a state-space model to address
the problem of incidence from non-specific surveillance data, and comparing the inference from an
ensemble of proposed models to address the uncertainty in the underlying dynamics. Our ensemble
approach suggests robust support for some general patterns of rotavirus dynamics. The peak trans-
mission is well estimated, with a maximum in early March, with little variation between models.
Rainfall, which is a primary driver of seasonality in the region, peaks in August. [5] found that early
March, when urban population density is at its maximum due to seasonal rural-urban migration,
was the peak season for transmission of measles. Though measles is transmitted through aerosolized
droplets, the similarity in the peak seasonality suggests that higher population density may also
facilitate transmission of rotavirus.
We find the SEIRS structure in Model C (model with incubation period) best explains the observed
data. In this model, subsequent infections have decreased levels of infectiousness and lower risk of
infection compared to the initial infection. All models except for Model A, which offers the worst fit
to the data, include this dynamic. The estimated basic reproductive number is fairly robust across
Models B-E. In particular, point estimates for models B-E vary from 10.3 to 13.9 in Table 1, though
Model A has a much larger R0.
There is an observed double peak in incidence (Figure 1) during the second year of observation
which our fitted models do not capture. However, this may be an anomaly, as the double peak is not
seen strongly during the first and third years. We note that our models are capable of reproducing
this behavior when the seasonal variation in transmission is stronger than the best fit estimate, via an
interaction between seasonal effects and the high birth rate in the region. More complex explanations
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for such double peaks have been observed elsewhere. In cholera, similar to rotavirus in transmission,
local ecological variations were responsible for bimodal incidence [13].
Our estimate of overall burden of severe RVGE is robust across Models B-E. In spite of the
fact that the full epidemiological processes are unknown, we can be fairly sure that the total yearly
burden among children under 5 is in the vicinity of 3.5% (Table 1). Model A predicts a 3-fold greater
incidence of severe RGVE; however, this model has the weakest support and model-averaged burden
is similar to Models B-E.
While uncertainty in retrospective dynamics and disease burden can be characterized using dif-
ferent models, additional uncertainty about the efficacy of proposed interventions limits the ability
to predict future dynamics and disease burden. [2] estimated that rotavirus vaccine could result in
2.46 million childhood deaths between 2011-2030. Of course, uncertainty in the seroconversion rate
[24] and achievable vaccination coverage means that the true benefit of these vaccines is unknown.
Here, we used the ensemble prediction to project the potential impact of rotavirus vaccination in the
Niger setting under two scenarios for vaccine efficacy; thus integrating both dynamic uncertainty due
to different models and sensitivity to the realized effectiveness of a vaccine program. Using a vaccine
efficacy derived from [24] we estimate that 70% coverage could result in 37-43% reduction in severe
RVGE in children under 5. [20] reported a lower efficacy from a 3-dose schedule in Niger; this would
lower the projected reduction of severe RVGE to 28-33%. Notably, although BMA estimates a total
reduction in yearly cases using both the efficacy reported in [24] and [20], it also predicts higher peaks
where more cases are observed than pre-vaccination. This short-term difference in cycle amplitude
for these models is a phenomenon anticipated by [33]. Anticipation of this shift in dynamic regime
caused by vaccination may be critical to the interpretation of short-term surveillance as the observa-
tion of higher peak incidence following the introduction of vaccination may be wrongly interpreted
as a failure in the vaccination program.
Dynamic models are a powerful tool to interpret disease surveillance data and anticipate the
potential consequences of interventions. The method we describe here addresses two main sources
of uncertainty: imperfectly observed data and scientific uncertainty about epidemiological dynamics.
Our methods also allow us to identify key epidemiological interpretations – transmission seasonality
and the proportional impact of vaccination – that are robust to model choice, and those that are
model dependent, that is, R0 and the annual burden of severe RVGE. By assessing the fit of the
observed surveillance to each model, we find that these latter measures are robust within the subset
of well supported models.
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We provide details below about the five different dynamic models along with information about
computational methods used to perform inference for each of them. In addition, we describe the
implemention of the Bayesian model averaging approach used in the manuscript.
A Model Details
Figure 6: Structure of the compartmental models adapted from [32].
The structure of the models is given in Figure 6, which we explain in detail below. Common
to each of the models we describe, we assume a time-varying transmission rate with a period of one
year to account for seasonality,
βi(t) = β0i
(
1 + b cos
(
2pit− 52φ
52
))
,
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where t is time in weeks, β0i is the baseline rate for age class i, and b and φ are the amplitude and
offset of the seasonal variation.
We also assume the birth rate µ(t) varies with time. The mean weekly birthrate is estimated by
µ¯ = 1/(5× 52). The variation in monthly birth rate is shown in Table 2. Finally, for each model we
assume a negative binomial observation process with mean equal to the number of weekly reported
cases and dispersion parameter r.
Table 2: Seasonal variation in birth rate in Niger, estimated from 1980-2000 using Demographic and
Health Surveys. [15] An amplitude of −.17 for January tells us the birth rate is 17% below the mean.
Month Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Amplitude -.17 .01 .03 .25 .12 .03 -.01 .09 .01 .13 -.31 -.17
We describe in detail the dynamics of each of the five models outlined in Figure 6. Model A [37, 3]
is an SIRS model in which severe and mild rotavirus are tracked separately. Severe infections have a
longer duration and contribute more to the overall force of infection. Following infection, there is a
period of temporary immunity that wanes over time. The model is age structured with age groups
0-1 month, 2-3 months, 4-5 months, 6-11 months, 1 year, and 2-5 years indexed by i. The differential
equations describing the model dynamics are:
Model A
dMi
dt
= αi−1M(i−1) − αiMi + µN − δMi (1)
dSi
dt
= αi−1S(i−1) − αiSi + δMi − λiSi + τRi (2)
dIs, i
dt
= αi−1Is,(i−1) − αiIs,i + λs,iSi − γsIs,i (3)
dIm, i
dt
= αi−1Im,(i−1) − αiIm,i + λm,iSi − γmIm,i (4)
Movement between age classes occurs at rates dependent on the length of the interval in weeks, α ={
1
8
,
1
8
,
1
8
,
1
24
,
1
48
,
1
144
}
. The force of infection for age class i is given by λi =
6∑
j=1
βj(t)Cij
(Is + 0.5Im)
Nj
,
assuming that relative infectiousness for mild infections is less than for severe RVGE. Here Cij repre-
sents the frequency of contact from age class i onto class j [17], and satisfies fiCij = fjCji where fi is
the fraction of the population in class i. We make the simplifying assumption that contact between
age groups is homogeneous. With the absence of data on rotavirus infections for children over 5 and
adults, we also assume the population of children under 5 is closed and consider child-child trans-
mission only. Infection with rotavirus is typically asymptomatic [32] or unreported for older children
and adults, but could potentially play a role in transmission. The contact matrix is
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C =

1 1 1 1 1 1
1 1 1 1 1 1
1 1 1 1 1 1
3 3 3 1 1 1
6 6 6 2 1 1
18 18 18 6 3 1

.
The differences in our age groups means that the contact matrix is not symmetric, for example
we assume the population from 2-5 years is 18 times larger than the population from 0-1 months.
After a period of maternal immunity (Mi), individuals can be susceptible (Si), infected with either
mild (Im,i) or severe (Is,i) rotavirus, or recovered (Ri). These represent the number of individuals
in each class. In (1) we see how the number of children protected by maternal immunity change
over time. Newborns are added to this class at rate µ and individuals leave this class when maternal
immunity wanes with rate δ, where the mean period of maternal immunity is assumed to be 13 weeks
(δ = 113 ).
When maternal immunity wanes children are susceptible to rotavirus infection. In (2), we see that
individuals enter the susceptible class when maternal immunity wanes. They become infected at a
rate given by the force of infection λi. After recovery, individuals may reenter the susceptible class
at rate τ , where the mean period of immunity following infection is fixed at one year (τ = 1/52).
Equation (3) models the change in total infections with severe rotavirus. We assume the proportion
of infections with severe rotavirus is lower than mild by setting λs,i = 0.24λi. Individuals leave
the infected with severe rotavirus for a mean period of one week (γs = 1) following which they
are considered to be recovered. Similarly, (4) tracks the total infections with mild rotavirus, with
λm,i = 0.76λi and a mean infectious period of just half a week (γm = 2).
Only a fraction of infections with rotavirus develop RVGE (fixed at 24%), and we assume only
severe cases are reported, so the expected number of reported cases for age class i is given by 0.24ρλiSi
where ρ is the reporting rate. We make the simplifying assumption for all models that ρ is constant
across time and does not vary by age group.
Model B [33] is an SIRS model allowing for successive infections in which a second, third or
subsequent infection will have a reduced susceptibility to infection and level of infectiousness. This
represents partial immunity granted through repeated infections. Only a fraction of individuals in
the a first or second infectious class are assumed to develop severe RVGE. The model dynamics are
described by as follows.
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Model B
dMi
dt
= αi−1M(i−1) − αiMi + µN − δMi
dS1i
dt
= αi−1S1(i−1) − αiS1i + δMi − λiS1i
dI1i
dt
= αi−1I1(i−1) − αiI1i + λiS1i − γ1I1i
dR1i
dt
= αi−1R1(i−1) − αiR1i + γ1I1i − τR1i
dS2i
dt
= αi−1S2(i−1) − αiS2i + τR1i − λ2iS2i
dI2i
dt
= αi−1I2(i−1) − αiI2i + λ2iS2i − γ2iI2i
dR2i
dt
= αi−1R2(i−1) − αiR2i + γ2I2i − τR2i
dS3i
dt
= αi−1S3(i−1) − αiS3i + τR2i + τR3i − λ3iS3i
dI3i
dt
= αi−1I3(i−1) − αiI3i + λ3iS3i − γ2I3i
dR3i
dt
= αi−1R3(i−1) − αiR3i + γ2I3i − τR3i
Here in addition to an initial period of maternal immunity, individuals can be in the susceptible,
infected, or recovered classes for their first (S1, I1, R1), second (S2, I2, R2), or third and subsequent
(S3, I3, R3) infections. The force of infection for age class i is given by λi =
6∑
j=1
βj(t)Cij
(I1j + 0.5I2j + 0.2I3j)
Nj
,
assuming that relative infectiousness decreases for subsequent infections. We assume the relative risk
of infection decreases for subsequent infections, setting λ2i = 0.62λi and λ3i = 0.37λi as in [32]. Only
13% of first infections and 3% of second infections are assumed to develop severe RVGE, based on
data from a Mexico cohort study [45]. So the expected number of reported cases for age class i is
given by ρλi(0.13S1i + 0.03S2i). Following [45], we assume that the mean infectious period for the
first infection is one week (γ1 = 1) and for subsequent infections is half a week (γ2 = 2).
Model C [12] is an SEIRS model, similar to Model B but allowing for an additional exposed or
incubation period. Individuals in the exposed class are infected but not yet infectious. The dynamic
equations are given by:
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Model C
dMi
dt
= αi−1M(i−1) − αiMi + µN − δMi
dS1i
dt
= αi−1S1(i−1) − αiS1i + δMi − λiS1i
dE1i
dt
= αi−1E1(i−1) − αiE1i + λiS1i − ξE1i
dI1i
dt
= αi−1I1(i−1) − αiI1i + ξE1i − γ1I1i
dR1i
dt
= αi−1R1(i−1) − αiR1i + γ1I1i − τR1i
dS2i
dt
= αi−1S2(i−1) − αiS2i + τR1i − λiS2i
dE2i
dt
= αi−1E2(i−1) − αiE2i + λiS2i − ξE2i
dI2i
dt
= αi−1I2(i−1) − αiI2i + ξE2i − γ2I2i
dR2i
dt
= αi−1R2(i−1) − αiR2i + γ2I2i − τR2i
dS3i
dt
= αi−1S3(i−1) − αiS3i + τR2i − λiS3i
dE3i
dt
= αi−1E3(i−1) − αiE3i + λiS3i − ξE3i
dI3i
dt
= αi−1I3(i−1) − αiI3i + ξE3i − γ2I3i
dR3i
dt
= αi−1R3(i−1) − αiR3i + γ2I3i − τR3i
The modeling assumptions are the same as Model B but for the addition of an exposed class for
the first, second, or subsequent infections (E1, E2, E3). We assume a mean exposed period of 1 day
(ξ = 7).
Model D [44] is an SIS model which also allows for successive infections with different levels of
infectiousness, but assumes there is no period of temporary immunity following infection. After four
infections individuals are assumed to be fully immune to infection. The dynamics are described as
follows.
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Model D
dMi
dt
= αi−1M(i−1) − αiMi + µN − δMi
dS1i
dt
= αi−1S1(i−1) − αiS1i + δMi − λiS1i
dI1i
dt
= αi−1I1(i−1) − αiI1i + λiS1i − γ1I1i
dS2i
dt
= αi−1S2(i−1) − αiS2i + γ1I1i − λ2iS2i
dI2i
dt
= αi−1I2(i−1) − αiI2i + λ2iS2i − γ2iI2i
dS3i
dt
= αi−1S3(i−1) − αiS3i + γ2I2i − λ3iS3i
dI3i
dt
= αi−1I3(i−1) − αiI3i + λ3iS3i − γ2I3i
dS4i
dt
= αi−1S4(i−1) − αiS4i + γ2I3i − λ4iS4i
dI4i
dt
= αi−1I4(i−1) − αiI4i + λ4iS4i − γ2I4i
The force of infection is λi =
6∑
j=1
βj(t)Cij(I1 + 0.5I2 + 0.2I3 + 0.2I4)
N
, assuming that relative in-
fectiousness decreases for subsequent infections. We also assume the relative risk of infection decreases
for subsequent infections, setting λ2i = 0.62λi and λ3i = λ4i = 0.37λi. Again, we assume only 13%
of first infections and 3% of second infections are assumed to develop severe RVGE. So the expected
number of reported cases in age group i is given by ρλ(0.13S1i + 0.03S2i).
Finally, Model E [1] is an SIR-SIS hybrid wherein following infection, individuals have a chance
to either return to the susceptible class or gain full immunity. The equations for the dynamics are as
follows.
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Model E
dMi
dt
= αi−1M(i−1) − αiMi + µN − δMi
dS1i
dt
= αi−1S1(i−1) − αiS1i + δMi − λiS1i
dI1i
dt
= αi−1I1(i−1) − αiI1i + λiS1i − γ1I1i
dS2i
dt
= αi−1S2(i−1) − αiS2i + κ1γ1I1i − λ2iS2i
dI2i
dt
= αi−1I2(i−1) − αiI2i + λ2iS2i − γ2iI2i
dS3i
dt
= αi−1S3(i−1) − αiS3i + κ2γ2I2i − λ3iS3i
dI3i
dt
= αi−1I3(i−1) − αiI3i + λ3iS3i − γ2I3i
dS4i
dt
= αi−1S4(i−1) − αiS4i + κ3γ2I3i − λ4iS4i
dI4i
dt
= αi−1I4(i−1) − αiI4i + λ4iS4i − γ2I4i
The chance of returning to the susceptible class varies by number of previous infections. Following
[1] we fix κ1 = 0.62, κ2 = 0.65, κ3 = 0.85. The remaining modeling assumptions are the same as for
models B-D.
A.1 Computational Details
Denote the observed data by C = {Ci,t; t ∈ (1, ..., tobs), i ∈ (1, ..., 6)} where Ci,t is the number of
reported cases in age group i during week t. Cases were observed over tobs = 118 weeks. Denote the
number of cases in age group i during week t predicted by our models by ξi(t). For Model A,
ξi(t) = 0.24ρλi,tSi,t
While for models B-E,
ξi(t) = ρλi,t(0.13S1i,t + 0.03S2i,t)
For each model, the periodic solution to the system of ODEs specified above determines the
number of reported cases in age group i during a given week. Model dynamics are integrated forward
using the deSolve [39] package in R until a periodic solution is reached. Solutions have a period of
one year; that is, starting from arbitrary initial conditions, we run the dynamics forward until our
expected number of cases is identical from one 52 week period to the next, to within a small tolerance;
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i.e.
6∑
i=1
t∗+52∑
t=t∗
|ξi(t)− ξi(t− 52)| <  = 0.01
In practice, numerical integration for 20 years was enough to ensure the periodic solution was reached.
After reaching a periodic solution, the models are integrated forward an additional 118 weeks to get
the expected number of reported cases (Ξi(t); t ∈ (1, ..., tobs), i ∈ (1, ..., 6)).
Define random variables Ni,t ∼ NB(Ξi(t), r). The likelihood is
L(C|Θ) =
6∏
i=1
tobs∏
t=1
fNi,t(Ci,t)
The number of observed reported cases is modeled as a Negative Binomial with mean equal to the
expected number of cases and dispersion parameter r.
Inference for our model parameters is done via Markov chain Monte Carlo (MCMC) for models
A-E. At each step of the Markov chain, new parameters Θ′ are proposed and the model dynamics are
integrated forward until the periodic solution Ξi(t; Θ
′) is reached in order to calculate L(C|Θ′). The
parameters estimated by MCMC are Θ = (b, φ, r, ρ, β0i; i ∈ (1, ..., 6)), including seasonal amplitude b,
seasonal phase φ, the dispersion r of the Negative Binomial observation process, the reporting rate
ρ, and the baseline transmission rate for age class β0i.
MCMC samples are obtained from the posterior distribution
pi(b, φ, r, ρ, β01, ..., β06|C) ∝ L(C|b, φ, r, ρ, β01, ..., β06)p(b)p(φ)p(r)p(ρ)
6∏
i=1
p(β0i)
where we take priors p(β0i) = N(20, 5), p(b) = Unif(0, 1), p(φ) = Unif(2, 2pi + 2), p(r) =
Gamma(0.001, 0.001), and p(ρ) = N(0.117, 0.06). The prior of our reporting rate ρ is centered
at 11.7%, determined from the estimated reporting rate from the cluster survey (42.9%) and the esti-
mated proportion of the population under 5 in the four districts that is covered by hospital surveillance
(27.3%, from 2009 census data). In practice, we find that our estimates are robust to the choice of
standard deviation of p(ρ).
Table 3 provides parameter estimates from five different models. Estimates of the strength of
transmission are similar for models B-D, higher for Model E and significantly lower for Model A.
The same holds true for the reporting rate (Model A’s estimate of the reporting rate is dramatically
lower, and does not agree with estimates from the cluster survey, evidence that it is performing
poorly). Notably, the estimated phase of the transmission φ is similar across all models (Table 3).
For reference, an estimated φ of 7.4 corresponds to a peak transmission in early March. This is quite
close to the period of peak night time brightness in Maradi as measured by satellite imagery [5].
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Table 3: Posterior means and 95% HPD intervals
Model b φ r ρ
A 0.50 (0.48,0.51) 7.4 (7.3,7.5) 1.5 (1.4,1.5) 0.039 (0.035,0.044)
B 0.41 (0.37,0.45) 7.4 (7.3,7.6) 2.6 (2.3,2.8) 0.096 (0.089,0.104)
C 0.42 (0.36,0.46) 7.4 (7.3,7.5) 2.5 (2.0,2.8) 0.097 (0.089,0.104)
D 0.30 (0.26,0.34) 7.2 (7.0,7.4) 2.7 (2.5,2.8) 0.098 (0.090,0.107)
E 0.32 (0.27,0.36) 7.1 (7.0,7.3) 2.6 (2.5,2.7) 0.109 (0.099,0.117)
A.2 Dynamics Accounting for Vaccination
Based on the results of [24] we assume that 63% of vaccinated individuals are successfully
seroconvert after a single dose. Our models with vaccination allow for the red transitions in Figure 6.
For example, Model B allows for transitions directly from Mi=1 and S1,i=1 to R1,i=2 on the first dose,
and from R1,i=2 and S2,i=2 to R2,i=3 on the second dose. The dynamics equations will be modified
by the following terms:
dMi=2
dt
= (1− sc)α1Mi=1 + ...
dS1,i=2
dt
= (1− sc)α1S1,i=1 + ...
dR1,i=2
dt
= (sc)α1Mi=1 + (sc)α1S1,i=1 + ...
dR1,i=3
dt
= (1− sc)α2R1,i=2 + ...
dS2,i=3
dt
= (1− sc)α2S2,i=2 + ...
dR2,i=3
dt
= (sc)α2R1,i=2 + (sc)α2S2,i=2 + ...
Where c is the coverage and s = 0.63 is the rate of seroconversion [24] for low socio-economic
settings. This means that an individual who is vaccinated with a single dose has a lower risk of
infection, comparable to the effect of recovering from a natural infection. Vaccination with a second
dose further reduces risk of infection.
In Model A, the risk of infection does not decline with the previous number of infections. Therefore,
an additional vaccinated state Vi is added to the model for age group i. Two additional input
parameters are required for the vaccine efficacy against severe and mild RVGE. We assume the
vaccination happens at 2 months, but the vaccine efficacy is equal to the efficacy predicted under
models B-E for the two dose strategy, ηs = .796 and ηm = .609.
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dMi=2
dt
= (1− c)α1Mi=1 + ...
dS1,i=2
dt
= (1− c)α1Si=1 + ...
dVi=2
dt
= (c)α1Mi=1 + (c)α1Si=1 + ...
dVi>2
dt
= αi−1V(i−1) − αiVi − (τ + λs,i(1− ηs) + λm,i(1− ηm))Vi
dSi>2
dt
= τVi + ...
dIs,i>2
dt
= λs,i(1− ηs)Vi + ...
dIm,i>2
dt
= λm,i(1− ηm)Vi + ...
Given our vaccination strategy for models B-E, the vaccine efficacy for severe RVGE after two
doses is 79.6%, in line with efficacy studies of rotavirus vaccines. This is calculated by multiplying the
proportion of individuals who are successfully immunized twice, once, or zero times by the expected
reduction in RVGE incidence for each case.
V E = 1−
[
0.372 × 1 + 2(0.37)(0.63)×
(
0.62
0.03
0.13
)
+ 0.632 ×
(
0.37
0
0.13
)]
= 79.6%. (5)
We assume following [45] that 47% of first infections and 25% of second infections and 32% of third
infections are assumed to develop any RVGE (mild RVGE is unreported). Therefore the vaccine
efficacy for all RVGE is
V E = 1−
[
0.372 × 1 + 2(0.37)(0.63)×
(
0.62
0.25
0.47
)
+ 0.632 ×
(
0.37
0.32
0.47
)]
= 60.9%.
In practice, first model parameters Θ are estimated via MCMC for the models without vaccination.
Using the fitted model, the dynamics are then integrated forward at the posterior mean of Θ until the
periodic solution has been reached. Then, the dynamics are modified to allow for transitions between
compartments by vaccination.
A.2.1 Projections Based on Vaccine Efficacy from a Recent Study
Recently [20] estimated that 3 doses of vaccine had 66.7% efficacy against severe RVGE among
children in Niger. Though we do not explicitly account for 3 doses of vaccine, we can calculate
the effective seroconversion rate for our model above that would yield this observed efficacy after a
complete sequence of doses. Thus, we set ηs = .667 and use (5) to calculate the effective seroconversion
rate as 49%. Then the vaccine efficacy for all RVGE is ηm = .515. We estimate the predicted impact
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of vaccination using different ηs, ηm and s values with the same dynamic equations.
Although we used the two dose strategy, by using different value of the efficacy, our study can
account for uncertainty in the seroconversion rate. Figures 7-9 are matched to Figures 3-5 in the
main paper. Because of the lower seroconversion rate, the projected results were qualitatively similar,
quantitatively smaller. Vaccination causes a shift in the age distribution across models (Figure 7),
with a higher proportion of RVGE cases occurring for older children.
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Figure 7: Distribution of cases across age groups observed in the data (black dots), predicted by the
models (red lines), and predicted after vaccination has been introduced at 70% coverage (blue lines).
Over the short term, Models A-E predict an overall decline in total burden, but an increase in the
magnitude of peak incidence (Figure 8).
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Figure 8: Relative incidence of severe RVGE after vaccination has been introduced into the models
assuming 70% coverge, out to five years after vaccination has been introduced. The vaccination has
been introduced at 0 year.
Figure 9 indicates that the short term trend of vaccination impacts based on BMA is similar to
that of Model C. BMA predicts 29.6% of long term reduction (99%CI : (28.0%, 32.7%)).
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Figure 9: Relative incidence of severe RVGE (Left), percent (Middle) and absolute (Right) long term
reduction in cases by coverage for Bayesian model averaging from the five fitted models. Dashed
lines denote 99% confidence interval. The vaccination has been introduced at 0 year. Variation in
reduction for a fixed (70%) level of coverage is demonstrated.
B Bayesian Model Averaging
For k = 1, ..., 5, consider Mk, the kth model, with prior p(Θk|Mk) and likelihood function
L(C|Θk,Mk). Note that we take the uniform model prior for p(Ml) and model evidence P (C|Mk)
is approximated via Bayesian information criterion (BIC) as in [34]. Then the posterior model
probability (PMP) for Mk given the observed data C is
p(Mk|C) = p(C|Mk)p(Mk)∑5
l=1 p(C|Ml)p(Ml)
,
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where
p(C|Mk) =
∫
L(C|Θk,Mk)p(Θk|Mk)dΘk
is the model evidence for Mk which measures how well each model is supported by the observed data.
Then the BMA estimate of the burden is
E[ξ(t)|C] =
5∑
l=1
E[ξl(t)|C,Ml]p(Ml|C).
A summary of our implementation of BMA is as follows: (1) We construct a separate MCMC
algorithm for each of the models A-E. (2) For each model, the burden estimate ξk(t) is evaluated for
the MCMC samples of the posterior distribution of that model. (3) The expected burden for model
k, E[ξk(t)|C,Mk], is estimated through the sample mean of the ξk(t)s obtained from Step (2). (4)
We take the weighted average of the burden across all models, with the weights equal to the posterior
model probabilities, p(Mk|C), obtained above.
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